Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies
chronic lymphocytic leukemia, primary systemic amyloidosis, Non-Hodgkin's lymphoma, solid tumors, myelofibrosis with myeloid metaplasia, and Waldenstrom Macroglobulinemia. It is also being increasedly used in combination with other chemotherapeutic agents for MM.
Contraindications:
Pregnancy
Dosing :
MoA :
Angiogenesis inhibitor:
Relapsed/refractory multiple myeloma: angiogenesis plays an important pathogenic role in multiple myeloma as reflected by increased bone marrow microvascular density and VEGF (vascular endothelial growth factor) levels.
VEGF receptors are overexpressed on blast cells in dysplastic marrows in MDS patients. Increased plasma levels of VEGF R have also been correlated with lower remission rate in patients with myelodysplastic syndromes
Lenalidomide treatment has also shown anti proliferative activity against MDS and MM cells in the absence of immune effector cells
